Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance

Eli Lilly And CoTrade
Royal Caribbean Cruises LtdTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs Royal Caribbean Cruises Ltd — how do they compare? Eli Lilly And Co trades at $1,221 (market cap $1.08T), while Royal Caribbean Cruises Ltd trades at $308 (market cap $82.15B). The key difference: Eli Lilly And Co is far larger — about 13.1× Royal Caribbean Cruises Ltd's market cap, and Royal Caribbean Cruises Ltd pays the higher dividend (1.63%). Which is the better fit depends on your goals.

LLYRCL
Market Cap
$1.08T$82.15B
Sector
HealthConsumer Cyclical
52-Week High
$1.24K$365.84
52-Week Low
$639.43$246.71
Enterprise Value
$1.13T$104.79B
Dividend Yield
0.57%1.63%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.

Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.

Royal Caribbean Cruises Ltd

Royal Caribbean (RCL) trades at $307.87, showing minimal daily movement (-0.04%) with a bullish technical signal. The company demonstrates strong fundamental momentum with Q2 2026 EPS beating expectations at $4.21 versus $3.98, and robust profitability metrics including 23.54% net income margin and 45.33% ROE. Recent news highlights strong demand trends and the pricing of $1.25 billion in senior notes to support growth initiatives.

RCL presents a compelling growth story with record bookings and improved financial health, though elevated valuation ratios (P/E 18.97, P/S 4.46) and geopolitical risks in Europe warrant caution. Analyst consensus remains positive with a $343.09 price target, suggesting approximately 11% upside potential from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY

About Royal Caribbean Cruises Ltd

Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.

Read more on RCL